What is PMCB's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for PMCB?

P/E (TTM) is n/a and 52-week range is $0.33 to $1.51 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s PMCB figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for PMCB?

The company profile lists revenue (TTM) near $39K, net income (TTM) near $-163M, EPS (TTM) near $-1.90 when available from the market-data feed. Figures are informational and may lag live markets.

Where is PharmaCyte Biotech Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Las Vegas, Nevada, US, 10.7M shares outstanding, ISIN US71715X2036 when available from company profile and filing metadata.

PharmaCyte Biotech Inc

$PMCB

Health Care · Biotechnology

IR Run Scenarios

$0.40

+1.76%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. The company is headquartered in Las Vegas, Nevada and currently employs 2 full-time employees. The company went IPO on 2003-09-11. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable, non-metastatic pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.

Employees

Website

pharmacyte.com/

IPO

2003-09-11

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)